Key Points
- Ra Capital Management, L.P. acquired 7,111 shares of Climb Bio on Jan. 5 at $3.50 each for a total of $24,888.50, bringing its direct holdings to 3,403,429 shares (about $11.9M) — a 0.21% increase in ownership.
- Ra Capital also added materially in December, buying 213,099 shares on Dec. 11 at $2.18 and 101,462 shares on Dec. 12 at $2.86 — roughly 314,561 shares for about $755k combined.
- Climb Bio (CLYM) trades around $4.20 with 50-/200-day SMAs of $2.76/$2.16, a market cap of ~$286M and a negative P/E, and carries mixed analyst coverage (average rating "Moderate Buy" with a consensus price target of $9.50).
Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) Director Ra Capital Management, L.P. acquired 7,111 shares of Climb Bio stock in a transaction that occurred on Monday, January 5th. The shares were bought at an average price of $3.50 per share, with a total value of $24,888.50. Following the transaction, the director directly owned 3,403,429 shares in the company, valued at approximately $11,912,001.50. This trade represents a 0.21% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, December 12th, Ra Capital Management, L.P. bought 101,462 shares of Climb Bio stock. The stock was bought at an average cost of $2.86 per share, for a total transaction of $290,181.32.
- On Thursday, December 11th, Ra Capital Management, L.P. bought 213,099 shares of Climb Bio stock. The stock was bought at an average price of $2.18 per share, for a total transaction of $464,555.82.
Climb Bio Stock Performance
Climb Bio stock opened at $4.20 on Thursday. The company has a 50-day simple moving average of $2.76 and a 200-day simple moving average of $2.16. The firm has a market capitalization of $286.36 million, a P/E ratio of -5.53 and a beta of -0.16. Climb Bio, Inc. has a one year low of $1.05 and a one year high of $5.05.
Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.03). As a group, sell-side analysts forecast that Climb Bio, Inc. will post -1.57 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several analysts recently commented on CLYM shares. William Blair started coverage on Climb Bio in a research report on Thursday, October 16th. They issued an "outperform" rating on the stock. HC Wainwright increased their price target on Climb Bio from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Thursday, December 18th. BTIG Research restated a "buy" rating and set a $8.00 price objective on shares of Climb Bio in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Climb Bio in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Climb Bio from a "hold" rating to a "strong sell" rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Climb Bio presently has an average rating of "Moderate Buy" and a consensus price target of $9.50.
Read Our Latest Research Report on CLYM
Institutional Trading of Climb Bio
Hedge funds and other institutional investors have recently modified their holdings of the company. Diadema Partners LP boosted its stake in Climb Bio by 4.8% during the second quarter. Diadema Partners LP now owns 702,135 shares of the company's stock valued at $871,000 after buying an additional 32,332 shares in the last quarter. Peapod Lane Capital LLC raised its position in Climb Bio by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 561,866 shares of the company's stock worth $1,129,000 after acquiring an additional 6,199 shares in the last quarter. Nan Fung Trinity HK Ltd. acquired a new stake in Climb Bio in the 2nd quarter valued at about $575,000. Shay Capital LLC boosted its position in shares of Climb Bio by 107.5% during the 2nd quarter. Shay Capital LLC now owns 415,000 shares of the company's stock valued at $515,000 after purchasing an additional 215,000 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of Climb Bio by 6.0% during the 3rd quarter. UBS Group AG now owns 405,404 shares of the company's stock valued at $815,000 after purchasing an additional 22,922 shares in the last quarter. Institutional investors own 69.76% of the company's stock.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
